AstraZeneca bolsters cancer arsenal with $2.4 billion Fusion buy

AstraZeneca (LSE: AZN) has taken a significant step towards revamping cancer treatment with a $2.4 billion acquisition of Fusion Pharmaceuticals^, a leader in next-generation radioconjugate therapies. This strategic move reinforces AstraZeneca’s commitment to offering patients … Read more

Why did AstraZeneca shares slump 8%

Yesterday, AstraZeneca (LSE: AZN) revealed that their groundbreaking precision drug aimed at tackling lung cancer showed slower progression than standard chemotherapy in a late-stage trial. However, this news was met with disappointment by investors, causing … Read more